logo

For the Inventor, By the Inventor

Ikeda, Japan

Yukimasa Nozaki

This inventor holds 7 USPTO granted patents. Top assignee: Takeda Chemical Industries, Inc.. Active years: 1978-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yukimasa Nozaki. Retrieved from https://idiyas.com/inventor/yukimasa-nozaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Ikeda, JA (1978)
  • Ikeda, JP (1986 - 1996)

Company Filing History:

goldMedal7 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1978-1996

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5498627 - Octahydro-2-naphthalenecarboxylic acid derivative, its production and use (1996-03-12),
2. 5147860 - TAN-1120, its derivatives, production and use thereof (1992-09-15),
3. 5135920 - Angiostatic agents (1992-08-04),
4. 4667027 - Cephem compounds and their production (1987-05-19),
5. 4656288 - Antibiotics, their production and use (1987-04-07),
6. 4587333 - Cephalosporins and their production (1986-05-06),
7. 4069316 - Method for producing antibiotic T-42082 and antibiotic T-42082 (1978-01-17),

Title: Yukimasa Nozaki: Innovator in Pharmaceutical Chemistry

Introduction

Yukimasa Nozaki is a prominent inventor based in Ikeda, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. His work focuses on developing novel compounds with therapeutic applications, particularly in cancer treatment.

Latest Patents

Nozaki's latest patents include innovative compounds such as the Octahydro-2-naphthalenecarboxylic acid derivative. This invention introduces a novel compound, TAN-1813, which exhibits farnesyltransferase-inhibitory, cell growth-inhibitory, and anti-tumor activities. The patent details the production of TAN-1813, its use as a farnesyltransferase-inhibiting agent, and its potential as an anti-tumor agent. Additionally, he has developed TAN-1120 and its derivatives, which are designed to inhibit angiogenesis, making them useful for the prophylaxis and therapy of diseases associated with abnormal angiogenesis, particularly tumors.

Career Highlights

Yukimasa Nozaki is currently associated with Takeda Chemical Industries, Inc., a leading pharmaceutical company. His work at Takeda has allowed him to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Nozaki has collaborated with notable colleagues, including Hideo Ono and Setsuo Harada. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Yukimasa Nozaki's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a key inventor in the field. His work continues to pave the way for new therapeutic options in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…